Ovine recombinant PrP as an inhibitor of ruminant prion propagation in vitro

Rob G. Workman, Ben C. Maddison, and Kevin C. Gough

School of Veterinary Medicine and Science, The University of Nottingham, Sutton Bonington, Leicestershire, UK; ADAS, The University of Nottingham, Sutton Bonington, Leicestershire, UK

ABSTRACT. Prion diseases are fatal and incurable neurodegenerative diseases of humans and animals. Despite years of research, no therapeutic agents have been developed that can effectively manage or reverse disease progression. Recently it has been identified that recombinant prion proteins (rPrP) expressed in bacteria can act as inhibitors of prion replication within the in vitro prion replication system protein misfolding cyclic amplification (PMCA). Here, within PMCA reactions amplifying a range of ruminant prions including distinct Prnp genotypes/host species and distinct prion strains, recombinant ovine VRQ PrP displayed consistent inhibition of prion replication and produced IC50 values of 122 and 171 nM for ovine scrapie and bovine BSE replication, respectively. These findings illustrate the therapeutic potential of rPrPs with distinct TSE diseases.

KEYWORDS. BSE, PMCA, prion diseases, protein inhibitors, recombinant PrP, Scrapie, therapeutics

INTRODUCTION

Prion diseases, also known as transmissible spongiform encephalopathies (TSEs), are fatal neurodegenerative diseases that affect humans and animals. Examples include scrapie in sheep, bovine spongiform encephalopathy (BSE) in cattle and Creutzfeldt Jakob disease (CJD) in humans. The central event in these diseases is the conversion of cellular prion protein (PrPc) into the pathogenic isoform PrPSc.1 However, the exact mechanism of conversion and the cause of pathogenesis remains unclear.

It is proposed that PrPSc propogates by a template conversion model, whereby PrPc is converted into further copies of PrPSc independently of nucleic acids.2 Through this mechanism PrPSc spreads throughout the central nervous system (CNS) of the host, eventually leading to the development of clinical

Correspondence to: Dr. Kevin C. Gough; School of Veterinary Medicine and Science, The University of Nottingham, Sutton Bonington Campus, College Road, Sutton Bonington, Leicestershire, LE12 5RD, UK; Email: kevin.gough@nottingham.ac.uk

Received 06 February 2017; Revised 16 May 2017; Accepted 12 June 2017.

© 2017 Rob G. Workman, Ben C. Maddison, and Kevin C. Gough. Published by Informa UK Limited, trading as Taylor & Francis Group

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The symptoms themselves are characterized by neuropathy and loss of cognitive function leading to death. These diseases are classically associated with long asymptomatic incubation periods.

The pursuit of therapeutics for prion diseases has been a research priority for over 2 decades, especially following the BSE epidemic in the United Kingdom from the mid-1980s to 1990s. This epidemic resulted in the transmission of BSE to humans, leading to the emergence of variant CJD (vCJD). A recent study has suggested that 1 in 2000 individuals may be carriers of the BSE PrPSc protein in the UK, highlighting the potential for iatrogenic transmission. Approaches to the development of therapeutics have included pharmacological, immunotherapeutics, protein and peptide inhibitors, immunopotentiators and many others. A number of compounds have even been taken as far as clinical studies, including pentosan polysulphate and quinacrine. However, neither of these compounds have been found to be effective in reducing disease progression in clinically-affected patients.

Recently it was reported that heterologous recombinant prion proteins (rPrPs) can act as inhibitors of prion amplification in vitro and in vivo, highlighting the potential for rPrPs as therapeutic agents for controlling or slowing the development of prion replication.

Here, we use the protein misfolding cyclic amplification (PMCA) assay as an in vitro model for prion replication. PMCA is a technique pioneered by Soto and colleagues and allows the amplification of minute quantities of PrPSc when seeded into a PrPC substrate and being subjected to rounds of incubation and sonication, this can include the periodic replenishment of PrPC substrate in a process termed serial PMCA (sPMCA). Using PMCA, rPrPs representing different ovine Prnp genotypes were tested as inhibitors of scrapie and BSE replication. In terms of ovine Prnp genotype, it is well documented that the VRQ genotype (codons 136, 154 and 171 of Prnp, respectively) is associated with high susceptibility to classical scrapie, and ARR is associated with high resistance. The ARQ genotype is susceptible to classical scrapie and different genotypes may be infected with different prion strains. The strains that were amplified included ovine TSEs with distinct prion strains, in hosts with distinct Prnp genotypes, and replication in PrPC substrate with distinct Prnp genotype (combinations are summarised in Table 1).

RESULTS

Bacterially expressed recombinant prion proteins were cloned, expressed and purified by immobilised metal affinity chromatography (IMAC) to the level of a single protein band on an SDS-PAGE gel (Fig. 1). Typical yields of the refolded recombinant proteins were 12 mg/L of culture.

rPrP proteins were assessed as inhibitors within in vitro PMCA reactions. TSE samples used are detailed in (Table 1). IC50 values were calculated for rVRQ, rARQ and rARR proteins when inhibiting the replication of a single ARQ/VRQ classical scrapie isolate (Fig. 2). rVRQ was the strongest inhibitor with a mean IC50, when calculated using the dot blot analysis method, of 122 nM, followed by rARQ (IC50 of 288 nM) and rARR (IC50 of 505 nM). The analysis of PMCA products inhibited by 1200 nM rVRQ or where no spike was present demonstrated that the dot blot method was detecting PrPSc and no residual PrPC signals were present (Fig. 2). Reanalysis of all samples by western blot further demonstrated the specific analysis of PrPSc and produced IC50 values that gave the same relative efficacy for the rVRQ, rARQ and rARR inhibition: 85, 200 and 515 nM, respectively (Fig. 2 and data not shown).

It was then determined whether the conformation of the rVRQ was required for inhibition to occur. Heat-denatured rPrP was used at 1200 nM along with non-denatured rVRQ and both inhibited replication of scrapie PrPSc. There was a trend for the denatured rVRQ to show less inhibition but this was not significantly different (p = 0.08; Fig. 3). Addition of a control protein (bovine serum albumin; BSA) to the reactions at 1200 nM did not inhibit replication which was only

...
inhibited by 0.08% (average of triplicate analysis) in the presence of this protein (unpaired Student’s t-test analysis gave a p value of 0.98; data not shown).

It was then determined whether rVRQ could bind scrapie PrPSc. After incubation with scrapie-affected brain, beads coated in rVRQ could seed PMCA reactions and this was not the case for beads lacking the recombinant protein (Fig. 4). On average, beads coated in rVRQ captured 32% of the PMCA seeding capability in the brain homogenate, without rVRQ only 6% of seeding activity was recovered.

A possible explanation for the greater efficacy of rVRQ as an inhibitor of the replication of this ARQ/VRQ classical scrapie isolate is the homologous sequence between the inhibiting protein, the PrPSc seed and/or PrPC substrate used for amplification (VRQ/ARQ).

Table 1. Prion disease isolates used in this study.

| Strain Type                  | Sample Number | Prnp genotype of host | Prnp genotype of PMCA substrate |
|------------------------------|---------------|-----------------------|---------------------------------|
| Classical Scrapie PG1361/05  | VRQ/ARQ       | VRQ/VRQ               |
| Classical Scrapie PG1563/02  | VRQ/VRQ       | VRQ/VRQ               |
| G338 Scrapie MC136477        | VRQ/VRQ       | VRQ/VRQ               |
| G338 Scrapie MC136553        | VRQ/VRQ       | VRQ/VRQ               |
| Apl338/Apl338ii Scrapie MC141403 | VRQ/VRQ      | VRQ/VRQ               |
| Apl338/Apl338ii Scrapie MC141404 | VRQ/VRQ      | VRQ/VRQ               |
| CH1641 Scrapie J2935         | AHQ/ARQ       | AHQ/AHQ               |
| Ovine BSE PG0392/04          | ARQ/ARQ       | VRQ/VRQ               |
| Ovine BSE PG1693/03          | ARQ/ARQ       | VRQ/VRQ               |
| Bovine BSE SE1929/0749       | Bovine        | Bovine                |
| Bovine BSE SE1945/0035       | Bovine        | Bovine                |
| Bovine BSE SE1762/0013       | Bovine        | Bovine                |

Classical scrapie and BSE infected brain material were field cases from the APHA (Addlestone, Surrey, UK). BSE samples SE1929/0749, SE1945/0035 and SE1762/0013 were pools of multiple isolates. Ovine BSE samples originated from ovine BSE challenges of sheep (APHA). CH1641 scrapie isolates were a gift from Professor N. Hunter, The Roslin Institute, (University of Edinburgh). Apl338ii and G338 scrapie brain tissue was isolated from a transgenic mouse bioassay (transgenic for ovine VRQ Prnp).29

FIGURE 1. Ovine PrPs rVRQ, rARQ and rARR purified by IMAC. A) Purification of rVRQ. Lane 1: rVRQ from urea solubilised washed inclusion body. Lane 2 to 9: elution fractions. B) Purification of rARQ. Lanes 1-6: elution fractions. C) Purification of rARR. Lanes 1-6: elution fractions. The inclusion body sample was 4.5 μL of a total of 30 mL produced from 1 L of bacterial culture. Each elution fraction is 4.5 μL of 5 mL total volume for each fraction. Molecular mass markers are indicated.
To determine whether absolute sequence identity was a requirement for the inhibition of prion replication, the 2 most effective inhibitors as determined by IC50, rVRQ and rARQ, were applied to bovine BSE PMCA amplification (Fig. 5). The mean IC50 values were 171 nM for rVRQ and 366 nM for rARQ.
VRQ rPrP was then tested as an inhibitor of the amplification of isolates over 5 rounds of sPMCA, different scrapie strains were analyzed as well as ovine and bovine BSE. (Table 1). These samples were chosen because of their efficient amplification over the course of 5 d of sPMCA. PMCA was performed in the presence of rVRQ at 400 nM which consistently inhibited rVRQ at 400 nM (Table 1). These samples were chosen because of their efficient amplification over the course of 5 d of sPMCA. PMCA was performed in the presence of rVRQ at 400 nM which consistently inhibited rVRQ at 400 nM.

**DISCUSSION**

Using PMCA as an *in vitro* model for prion replication, ovine PrP was shown to inhibit the replication of VRQ/ARQ scrapie prion in VRQ/VRQ substrate with rVRQ, rARQ and rARR producing mean IC50 values of 122, 288 and 505, respectively (calculated from dot blot analysis of PMCA products). For the inhibition of bovine BSE replication in bovine substrate, the mean IC50 values were 171 nM for rVRQ and 366 nM for rARQ. These data indicate that VRQ was the stronger inhibitor and could inhibit prion replication in the absence of absolute sequence identity with substrate or seed PrP.

Effective concentration 50% (EC50) values have been reported by Yuan et al. when analyzing inhibition with rPrP homologous to the seed and substrate PrP sequence.15 The models used were for human rPrP23–231 (129V) inhibition of iCJDVV2 (iatrogenic CJD, PRNP valine 129 homozygous) amplification in TgWV murine (transgenic for human 129V PRNP) substrate, where the approximate EC50 value was 60 nM, and mouse rPrP23–231 inhibition of mouse PrPSc (strain 139A) amplification in mouse brain homogenate where the approximate EC50 value was 120 nM. These figures are similar to the IC50 values determined in the present study for rVRQ inhibition of homologous genotype seed/substrate.

Here, inhibition was also demonstrated with PrPSc seeds from bovine and ovine hosts, including ovine hosts with distinct Prnp genotypes, and with distinct prion strains, and also when amplification was within substrate with different Prnp genotypes (Table 1, Fig. 6). These data indicate that rVRQ may act as a ‘universal inhibitor’ of ruminant prion replication *in vitro*. 

---

**FIGURE 3.** Both native and denatured rVRQ inhibit prion replication. PMCA amplification of a scrapie isolate (PG1361/05) was performed in triplicate in the presence of 1200 nM of rVRQ with or without denaturation or in the absence of any rPrP (as indicated). 6.7 μL of PK digested PMCA reaction was analyzed by western blotting using monoclonal antibody SHa31 (A). Following densitometry, signals were expressed as the percent inhibition, calculated using the no rPrP controls as 100% amplification (B). No significant difference in the inhibition levels between rVRQ and denatured rVRQ was observed (unpaired Student’s t-test, p = 0.08). Molecular mass markers are indicated.
The mechanism of rPrP inhibition remains unresolved. In terms of the binding ability of rPrP, Yuan et al.\textsuperscript{15} demonstrated that human rPrP\textsubscript{23–231} bound to PrP\textsuperscript{Sc} (iCJD) but not PrP\textsuperscript{C}, and Meier et al. report that murine rPrP binds murine adapted scrapie PrP\textsuperscript{Sc}.\textsuperscript{21} The present study also demonstrates that rVRQ bound to ovine scrapie PrP\textsuperscript{Sc} which was then able to seed PMCA reactions. It has been previously suggested that rPrP inhibition is species specific and correlates to sequence similarity.\textsuperscript{22} Here the majority of scrapie strains and ovine BSE used were amplified in a VRQ/VRQ substrate (Table 1) and inhibited with rVRQ. Sequence similarity between inhibitor and seed/substrate may well be important and the most effective inhibition was seen with rVRQ inhibition of seed/substrate with homologous Prnp genotype. However, the presented data also indicates that the mechanism for inhibition is not wholly dependent on such sequence similarity. Both rVRQ and rARQ proteins inhibited bovine BSE amplification in bovine brain homogenate substrate, suggesting that the inhibitory activity of these proteins may be independent of sequence similarity. This is further supported by experiments with rVRQ inhibiting different TSE isolates/strains and in prion amplification reactions with substrates of heterologous genotypes. Here, it was also shown that heat denatured rVRQ could inhibit ovine scrapie replication indicating that rPrP conformation is not a major influence on the mechanism of inhibition. It may suggest that internal unstructured PrP amino acid linear sequences are involved in interactions with PrP\textsuperscript{Sc} that facilitate inhibition of prion replication. However, this assumes that incubation of the denatured rPrP at 37°C during PMCA does not promote full refolding of rVRQ. Using mouse and hamster prion replication models, internal rPrP peptides have previously been shown to inhibit prion replication and such peptides include the region that in sheep contains the 136 polymorphism (hamster PrP residues 109-141).\textsuperscript{23,24} These studies also show that inhibition by this peptide is effective across species where there is not absolute amino acid sequence identity.\textsuperscript{24} This supports other studies using cell-

FIGURE 4. rVRQ binds to PrP\textsuperscript{Sc}. Beads were coated with rVRQ (rVRQ-beads capture) or had no rPrP present (bead capture) and were then incubated with brain homogenate from a scrapie-affected sheep (PG1361/05). Following extensive washing, the beads were used to seed PMCA reactions along with beads that had not been incubated with any brain sample (beads only). PMCA products were digested with PK and analyzed for PrP\textsuperscript{Sc} with antibody SHA31 (A). Following densitometry, signals were expressed as the percent amplification compared with a control reaction directly spiked with an equivalent level of PrP\textsuperscript{Sc} (PrP\textsuperscript{Sc} seed) as 100% amplification after the background signals for beads only reactions were removed (B). The difference in PMCA seeding between beads with and without rVRQ was significantly different (unpaired Student’s t-test, \( p = 0.03 \)). Molecular mass markers are indicated.
free conversion reactions where heterologous PrP\(^\text{Sc}\) has been demonstrated to effectively inhibit homologous PrP\(^\text{Sc}\) conversion.\(^\text{25}\) If the analogous linear stretch of residues within rPrP described by Chabray and colleagues\(^\text{23,24}\) influences binding of ovine rPrP to ruminant PrP\(^\text{Sc}\) and inhibition of replication, then the 136 polymorphism may influence the efficacy of this process but inhibition of differing PrP\(^\text{Sc}\) primary sequences should be possible, as appears to be the case in the present study.

The inhibitory mechanism of rPrPs may be in part due to the lack of secondary modifications. Different glycosylation states of PrP can selectively affect prion strain amplification.\(^\text{26}\) rPrPs then may act as competitive, but less conversion efficient substrates due to the lack of secondary modifications.\(^\text{15,16,21}\) This may be aided by the concentration of inhibitor used here (400 nM) and by Yuan et al.\(^\text{15}\) (200 nM), which are far greater than physiological concentrations of PrP\(^\text{C}\) (~13 nM in 10% ovine brain homogenate, calculated from the values reported elsewhere\(^\text{27}\)). The reported data from an in vitro model indicates that rVRQ is a therapeutic candidate that requires examination in vivo using transgenic mice. In a recent study, RML-chandler scrapie disease progression in mice was increasingly delayed in response to increasing doses of hamster rPrP. This study suggested that the stoichiometry of host PrP\(^\text{C}\) to rPrP could be an important factor in the inhibitory mechanism and importantly, demonstrated that rPrPs have therapeutic effects in vivo.\(^\text{16}\)

Why the rVRQ protein acts as an inhibitor of replication for a range of TSE isolates and strains is unexplained, but PrP proteins containing the ovine Q\(_{171}\) polymorphism are known to act as superior amplification substrates even to other prion types like BSE.
and vCJD. This may indicate that VRQ PrP can effectively interact with PrPSc from different sources and this may then explain the inhibitory activity across prion types with rVRQ acting as a competitive inhibitor. The reported inhibitory activity of rVRQ highlights the potential application of recombinant PrP proteins as broad-spectrum inhibitors of prion replication. Whether this rVRQ inhibition of ruminant prion replication extends to further host species and prion strains remains to be established.

**MATERIAL AND METHODS**

**Samples**

Healthy and diseased ovine tissues were obtained from the Animal and Plant Health Agency TSE-Archive (APHA, Addlestone, Surrey, UK). Classical scrapie infected brain material was obtained from scrapie positive specimens submitted to the APHA for testing. Ovine BSE samples originated from ovine BSE challenges of sheep performed by the APHA. The CH1641 scrapie isolate was a gift from Professor N. Hunter, The Roslin Institute, (Neuropathogenesis Division, University of Edinburgh). BSE positive bovine brain samples were pools of 71 BSE positive cases (SE1929/0749 and SE1945/0035) or were a pool of 4 isolates (SE1762/0013), all 3 samples were sourced from the APHA. Apl338ii and G338 scrapie brain tissue was derived from a transgenic mouse bioassay (transgenic for ovine VRQ PRNP) as described. All TSE samples used are detailed in Table 1. 10% (w/v) brain homogenates were prepared as described previously. Healthy ovine brain tissue was obtained from a scrapie-free, New Zealand derived flock (ARSU, APHA) and bovine brain tissue from a confirmed BSE negative Fresian cow.

**Production of Recombinant PrP Proteins**

*Prnp* genes for ovine PrP VRQ (23–231) and ARR (23–231) were amplified by PCR from genomic DNA isolated from sheep of known
genotype using the primers: Ov PrP pET F 5'-AGAATTCCATATGAGCAAGAAGCGTCCAA AACCTGCCGAGAGATG-3' and Ov PrP pET R 5'-ACTCAGATCTCATAACTTGCCCCA CGTTGTAATAAGCCTGGATTTCGAT-3'. Products were digested with NdeI and BamHI and ligated into plasmid pET22b at NdeI and BamHI sites. The sequences of the Prnp inserts were confirmed by Sanger sequencing. The construct for the ovine recombinant protein ARQ (23–231) in the expression plasmid pET41 (aC) was obtained from IDEXX Laboratories.

VRQ and ARR recombinant proteins were expressed in Novablue (DE3) E. coli, and ARQ recombinant protein was expressed in Top10 E. coli. Briefly, bacterial cultures were grown in 2YT containing 100 μg/mL ampicillin (VRQ, ARR) or 50 μg/mL kanamycin (ARQ), and at mid log growth were induced by addition of 1 mM Isopropyl β-D-1-thiogalactopyranoside. Cultures were incubated shaking at 37°C overnight. Cells were then harvested by centrifugation at 2800 g for 30 minutes and stored at −20°C before lysis. Cell pellets were resuspended in lysis buffer (50 mM NaH2PO4, 300 mM NaCl, pH 8.0, 0.1% Nonidet P-40, 10 mg/mL lysozyme, and Roche complete protease inhibitor without EDTA) and then incubated at 37°C for 1 hour. DNase I (1 mg/mL, 240 μL) and 120 μL MgCl2 (1 M) were added and incubated at room temperature for 15 minutes. Lysate was centrifuged at 12000 g for 20 minutes at 4°C. The pellets were then resuspended in 25 mL wash buffer (10 mM Tris pH 8.0, 0.1% Nonidet P-40) and incubated on ice for 20 minutes and pellets recovered by centrifugation as before. Washing was repeated 3 times. Pellets were resuspended in 2.5 mL solubilisation buffer (8 M urea, 50 mM NaH2PO4, 300 mM NaCl, pH 7.5) overnight at room temperature with rotation. Samples were centrifuged as before and supernatant purified by FPLC using an IMAC Hi-Trap chelating column (5 ml) (GE healthcare) pre-charged with copper sulfate. Protein was refolded on the column as described previously31 and then eluted on a 0–0.5 M imidazole gradient in 300 mM NaCl/50 mM NaH2PO4 (elution buffer). Protein fractions from the elution peak were assessed for purity by SDS-PAGE, staining with Instant Blue (Expedeon). Protein concentrations were determined by Bradford assay against a BSA standard. Protein fractions were pooled and stored at −80°C with 20 % (w/v) sucrose. rPrP was used as an inhibitor directly in PMCA reactions to determine inhibitor concentration 50% (IC50) values for inhibition of the classical scrapie PG1361/05. For subsequent PMCA experiments, imidazole and sucrose were removed from protein preparations by 2 rounds of dialysis against PMCA conversion buffer (50 mM NaCl, 4 mM EDTA (pH 8), 1% (v/v) Triton X-100, pH 7.4). Protein concentrations were determined by Bradford assay.

**Protein Misfolding Cyclic Amplification**

PMCA reactions were performed as described previously.32 Briefly, substrate, PrPSc “spike” and rPrP were combined in clear 0.2 mL PCR tubes (Corning). PMCA was performed at 37°C at a power setting of 190-200 W in an ultrasonicating water bath (model 3000; Misonix). Sonication was performed for 40 seconds followed by 29 minutes and 20 seconds of incubation, this cycle was repeated for 24 hours. For serial PMCA (sPMCA) experiments, 50 μL of reaction products were then added to 100 μL of fresh substrate (including appropriate inhibitors) and 100 μL of this was used in the subsequent round of PMCA. Reaction products were stored at −20°C before analysis. Reactions to determine relative IC50 values were prepared with 88 μL of brain homogenate substrate and rPrP to a total volume of 95 μL. For amplification of PG1361/05 only, sucrose was added to a final concentration of 2% (w/v). The concentration of each rPrP was adjusted before use by dilution in elution buffer. PrPSc “spike” (5 μL) was then added. Reactions were performed in triplicates and run for a single round of PMCA. IC50 values were determined for amplification of a classical scrapie isolate (PG1361/05) and a bovine BSE isolate (SE1762/0013). For scrapie amplification, concentrations of rPrPs of 50 nM, 100 nM, 200 nM, 400 nM, 800 nM and 1200 nM were analyzed with amplifications of 1% (w/v)
scrapie brain homogenate in VRQ/VRQ brain homogenate substrate. Controls included uninhibited PMCA reaction controls without any inhibitor present and reactions treated with 1200 nM rVRQ as 100% inhibition controls. For bovine BSE amplification, PMCA was performed using 10% (w/v) BSE brain homogenate (due to lower amplification efficiencies) in bovine brain homogenate substrate and a dilution series of 50 nM, 100 nM, 200 nM, 400 nM and 800 nM recombinant proteins. All triplicates were each analyzed by dot blot in duplicate and IC50 values were then calculated using the mean value for each inhibitor concentration. The experiments to determine IC50 values were repeated 3 times and the mean IC50 value for each inhibitor across all experiments reported. Western blot analysis of some of the samples was also performed, analyzing triplicate sPMCA reactions for each inhibitor concentration and the IC50 value determined using a mean values for each condition.

When assessing the inhibition of scrapie isolate PG1361/05, PMCA reactions were also performed in triplicate in the presence of 1200 nM of BSA, non-denatured rVRQ or rVRQ denatured by heating to 100°C for 10 minutes and cooling immediately on ice. Dialysed VRQ was also tested as an inhibitor of the amplification of a range of isolates. Reactions were prepared as described above using 400 nM of VRQ rPrP only. Reactions were spiked with 5 μL of 1% (w/v) brain homogenate for each isolate, except for CH1641 isolate J2935, and bovine BSE samples SE1929/0749 and SE1945/0035 which were spiked at 5 μL 10% (w/v) homogenate due to lower amplification efficiencies. All reactions were performed in duplicate for 5 rounds of sPMCA. For PrPSc detection, 20 μL of PMCA product was digested with PK and 6.7 μL of PMCA reaction analyzed by western blotting.

**Capture of PrPSc with rVRQ**

rVRQ was immobilised to tosylactivated magnetic beads following the manufacturer’s instructions (Invitrogen). Briefly, 10 mg of beads were reacted with 200 μg of rVRQ in 0.1 M borate buffer overnight at 37°C with shaking. Beads were washed 3 times in TBS and incubated with 33.5 μL of 10% (w/v) brain homogenate PG1361/05 for 1 hour at room temperature with rotation. Beads were then washed 5 times in TBS. An equivalent experiment was performed without any rVRQ. Beads (150 μg) from these 2 experiments along with beads that had not been incubated with brain homogenate were then used to spike duplicate PMCA reactions. PrPSc amplification was compared with reactions spiked directly with 5 μL of 1% (w/v) brain homogenate from PG1361/05.

**Western Blots and Dot Blots**

PMCA reaction products were digested with 50 μg/mL proteinase K (PK), 0.045% (w/v) SDS for 1 hour at 37°C and then boiled in LDS loading buffer (Invitrogen). PMCA product (0.83 μL) was spotted onto nitrocellulose, blocked with 3% (w/v) milk powder and probed with the monoclonal antibody SHa31 at a dilution of 1:40000 in 0.5% (w/v) milk powder and 0.5% (v/v) tween 20 in TBS buffer (50 mM Tris-HCl pH 8, 150 mM NaCl) (TBST). Bound antibody was detected with polyclonal goat anti-mouse-horseradish peroxidase (HRP) (Dako) at a dilution of 1:20000 in 0.5% (w/v) milk powder TBST. Membranes were then incubated with HRP substrate from an EZ-Chemiluminescence Detection Kit (Geneflow) and signals detected using a Photek Photon Counting System. Images were analyzed using ImageJ software. 1200 nM rVRQ treated reactions were measured as background readings and subtracted from the other signals. Percent inhibition values were then calculated relative to the mean intensity of uninhibited control reactions. Calculated values were plotted using GraphPad Prism and IC50 values were determined by nonlinear regression, log inhibitor verses response (variable slope) model with constraints at 100% and 0%. This model calculated the IC50 value from the data and did not assume a sigmoidal relationship. Some data sets were reanalysed by western
blots as described previously\textsuperscript{30} and analyzing 6.7 $\mu$L of PMCA product. Prion detection steps and densitometry analysis were as for dot blots.

**ABBREVIATIONS**

- **BSE**: Bovine Spongiform Encephalopathy
- **CJD**: Creutzfeldt Jakob Disease
- **PMCA**: Protein Misfolding Cyclic Amplification
- **PrP**: Prion Protein
- **rPrP**: recombinant PrP
- **TSE**: Transmissible Spongiform Encephalopathy

**DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST**

The authors declare no conflict of interest or competing financial interests.

**ACKNOWLEDGMENTS**

CH1641 material was a gift from Professor Nora Hunter (Roslin Institute). Healthy ovine brain and prion containing brain material was provided by the APHA biological archive.

**FUNDING**

This work was supported by the Biotechnology and Biological Sciences Research Council [grant number BB/J014508/1].

**REFERENCES**

[1] Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science 1982; 216(4542):136-44; PMID:6801762; https://doi.org/10.1126/science.6801762

[2] Prusiner SB. Prions. Proc Natl Acad Sci U S A 1998; 95(23):13363-83; PMID:9811807; https://doi.org/10.1073/pnas.95.23.13363

[3] Jucker M, Walker LC. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 2013; 501(7465):45-51; PMID:24005412; https://doi.org/10.1038/nature12481

[4] Trevitt CR, Collinge J. A systematic review of prion therapeutics in experimental models. Brain 2006; 129(Pa 9):2241-65; PMID:16816391; https://doi.org/10.1093/brain/awl150

[5] Lukan A, Vranac T, Curin Šerbek V. TSE diagnostics: Recent advances in immunoassaying prions. Clin Dev Immunol 2013; 2013:360604; PMID:23970925; https://doi.org/10.1155/2013/360604

[6] Rigter A, Langeveld JPM, van Zijderveld FG, Bossers A. Prion protein self-interactions: A gateway to novel therapeutic strategies? Vaccine 2010; 28 (49):7810-23; PMID:20932490; https://doi.org/10.1016/j.vaccine.2010.09.012

[7] Hill AF, Desbruslais M, Joiner S, Sidle KC, Golland I, Collinge J, Doey LJ, Lantos P. The same prion strain causes vCJD and BSE. Nature 1997; 389(6650):448-50, 526; PMID:9333232; https://doi.org/10.1038/38925

[8] Gill O, Spencer Y, Richard-Loendt A. Prevalent abnormal prion protein in human appendix after bovine spongiform encephalopathy epizootic: Large scale survey. BMJ 2013; 347:f5675; PMID:24129059; https://doi.org/10.1136/bmj.f5675

[9] Panegyres PK, Armani E. Therapies for human prion diseases. Am J Neurolgene Dis 2013; 2(3):176-86; PMID:24093082

[10] Barret A, Tagliavini F, Forlorni G, Bate C, Salmona M, Colombo L, De Luigi A, Limido L, Suardi S, Rossi G, et al. Evaluation of quinacrine treatment for prion diseases. J Virol 2003; 77(15):8462-9; PMID:12857915; https://doi.org/10.1128/JVI.77.15.8462-8469.2003

[11] Bone I, Belton L, Walker AS, Darbyshire J. Intraventricular pentosan polysulfate in human prion diseases: An observational study in the UK. Eur J Neurol 2008; 15(5):458-64; PMID:18355301; https://doi.org/10.1111/j.1468-1331.2008.02108.x

[12] Tsuboi Y, Doh-Ura K, Yamada T. Continuous intraventricular infusion of pentosan polysulfate: Clinical trial against prion diseases: Symposium: Prion diseases - Updated. Neuropathology 2009; 29 (5):632-6; PMID:19788637; https://doi.org/10.1111/j.1440-1789.2009.01058.x

[13] Collinge J, Gorham M, Hudson F, Kennedy A, Keoghi P, Pal S, Rossor M, Rudge P, Siddique D, Spyer M, et al. Safety and efficacy of quinacrine in human prion disease (PRION-1 study): A patient-preference trial. Lancet Neurol 2009; 8(4):334-44; PMID:19278902; https://doi.org/10.1016/S1474-4422(09)70049-3

[14] Geschwind MD, Kuo AL, Haman A, Devereux G, Raudabaugh BJ, Johnson DY, Torres-Chae CC, Finley R, Garcia P, et al. Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease. Neurology 2013; 81(23):2015-23; PMID:24122181; https://doi.org/10.1212/WNL.0b013e3182a9f3b4

[15] Yuan J, Zhan YA, Abiksharon R, Xiao X, Martinez MC, Zhou X, Kneale G, Mikol J, Lehmann S, Surewicz WK, et al. Recombinant human prion protein inhibits prion propagation in vitro. Sci Rep 2013; 3:2911; PMID:24105336; https://doi.org/10.1038/srep02911
[16] Skinner PJ, Kim HO, Bryant D, Kinzel NJ, Reilly C, Priola SA, Ward AE, Goodman PA, Olson K, Seelig DM. Treatment of prion disease with heterologous prion proteins. PLoS One 2015; 10(7):e0131993; PMID:26134409; https://doi.org/10.1371/journal.pone.0131993

[17] Saborio GP, Permanne B, Soto C. Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. Nature 2011; 411:810-3; https://doi.org/10.1038/35081095

[18] Saá PJ, Castilla J, Soto C. Presymptomatic detection of prions in blood. Science 2006; 313:92-94; PMID:16825570; https://doi.org/10.1126/science.1129051

[19] Hunter N. Scrapie and experimental BSE in sheep. Br Med Bull 2003; 66(1):171-83; PMID:14522858; https://doi.org/10.1093/bmb/66.1.171

[20] Spiropoulos J, Casalone C, Caramelli M, Simmons MM. Immunohistochemistry for PrPSc in natural scrapie reveals patterns which are associated with the PrP genotype. Neuropathol Appl Neurobiol 2007; 33:398-409; PMID:17617872; https://doi.org/10.1111/j.1365-2990.2007.00800.x

[21] Meier P, Genoud N, Prinz M, Maissen M, Rülicke T, Zurbriggen A, Raebel AJ, Aguzzi A. Soluble dimeric prion protein binds PrP(Sc) in vivo and antagonizes prion disease. Cell 2003; 113:49-60; PMID:12679034; https://doi.org/10.1016/S0092-8674(03)00201-0

[22] Priola SA, Caughey B, Race RE, Chesebro B. Heterologous PrP molecules interfere with accumulation of protease-resistant PrP in scrapie-infected murine neuroblastoma cells. J Virol 1994; 68(8):4873-8; PMID:7913509

[23] Chabry J, Caughey B, Chesebro B. Specific inhibition of in vitro formation of protease-resistant prion protein by synthetic peptides. J Biol Chem 1998; 273(21):13203-7; PMID:9582363; https://doi.org/10.1074/jbc.273.21.13203

[24] Chabry J, Priola SA, Wehrly K, Nishio J, Hope J, Chesebro B. Species-independent inhibition of abnormal prion protein (PrP) formation by peptide containing a conserved PrP sequence. J Virol 1999; 73(8):6245-50; PMID:10400714

[25] Horuchi M, Priola SA, Chabry J, Caughey B. Interactions between heterologous forms of prion protein: Binding, inhibition of conversion, and species barriers. Proc Natl Acad Sci U S A 2000; 97(11):5836-41; PMID:10811921; https://doi.org/10.1073/pnas.110523897

[26] Nishina KA, Deleault NR, Mahal SP, Baskakov I, Luhrs T, Riek R, Supattapone S. The stoichiometry of host PrPc glycoforms modulates the efficiency of PrPSc formation in vitro. Biochemistry 2006; 45(47):14129-39; PMID:17115708; https://doi.org/10.1021/bi061526k

[27] Moudjou M, Frobert Y, Grassi L, La Bonnardie C. Cellular prion protein status in sheep: Tissue-specific biochemical signatures. J Gen Virol 2001; 82(Pt 8):2017-24; PMID:11458009; https://doi.org/10.1099/0022-1317-82-8-2017

[28] Houston F, Goldmann W, Foster J, González L, Jeffrey M, Hunter N. Comparative susceptibility of sheep of different origins, breeds and PRNP genotypes to challenge with bovine spongiform encephalopathy and scrapie. PLoS One 2015; 10(11):e0143251; PMID:26587837; https://doi.org/10.1371/journal.pone.0143251

[29] Maddison BC, Spiropoulos J, Vickery CM, Lockey R, Owen JP, Bishop K, Baker CA, Gough KC. Incubation of ovine scrapie with environmental matrix results in biological and biochemical changes of PrPSc over time. Vet Res 2015; 46(1):46; PMID:25928902; https://doi.org/10.1186/s13567-015-0179-y

[30] Owen JP, Maddison BC, Whitelam GC, Gough KC. Use of thermolysin in the diagnosis of prion diseases. Mol Biotechnol 2007; 35(2):161-70; PMID:17435282; https://doi.org/10.1007/BF02686111

[31] Zahn R, von Schroetter C, Wüthrich K. Human prion proteins expressed in Escherichia coli and purified by high-affinity column refolding. FEBS Lett 1997; 417(3):400-4; PMID:9409760; https://doi.org/10.1016/S0014-5793(97)01330-6

[32] Taema MM, Maddison BC, Thorne L, Bishop K, Owen J, Hunter N, Baker CA, Terry LA, Gough KC. Differentiating ovine BSE from CH1641 scrapie serial protein misfolding cyclic amplification. Mol Biotechnol 2012; 51(3):233-9; PMID:21987099; https://doi.org/10.1007/s12033-011-9460-0

[33] Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 2012; 9(7):671-5; PMID:22930834; https://doi.org/10.1038/nmeth.2089